According to the “information notice on drug production supervision and inspection of Anhui Province” (July 2020) published on the website of Anhui Provincial Drug Administration on October 15, a total of 15 batches of drugs and relevant batches were inspected, including 12 batches of qualified samples and 3 batches of unqualified samples. According to the calculation of China economic network, the unqualified batch rate is 20%. Among them, Anhui Renhe Pharmaceutical Co., Ltd. In addition, SZ Pharmaceutical Co., Ltd. received a letter from SZ Pharmaceutical Co., Ltd. < p > < p > it is found that in the “2015 daily supervision plan of pharmaceutical and cosmetic production” issued by Anhui Provincial Drug Administration, the inspection conclusion of Anhui Renhe Pharmaceutical Co., Ltd. is not in line with the requirements. The inspection mode, year and scope include GMP compliance inspection, tablets (including hormones), hard capsules, granules, pills (water pills, honey pills) (including pretreatment and extraction of traditional Chinese Medicine), and inspection The inspectors are Zhou Pengcheng, Yuan Jie and Yu Xiaomei. The inspection time is from July 25 to 27, 2020. The treatment measure is to transfer the investigation and treatment of the Branch Bureau. At present, the enterprise has completed the rectification. < / P > < p > in addition, the inspection also found that Tianchang Yifan Pharmaceutical Co., Ltd. basically met the requirements. The inspection method, year and scope were “double random” routine inspection. The inspectors were Jiang Yansong, Yin Pengjun and Zhu Yelin. The inspection time was July 23-24, 2020, and the treatment measure was drug inspection warning letter. At present, the enterprise has completed the rectification. According to the inquiry of China economic network, Anhui Renhe Pharmaceutical Co., Ltd. was established in 2002 by the former Fuyang No.2 pharmaceutical factory and the former Anhui Dongfang pharmaceutical factory after restructuring. The company moved its address in 2003 and completed the construction in June 2004. It passed the “GMP certification” for the first time in August 2004, passed the “drug GMP certification” again in August 2009, and passed the “new GMP certification” in June 2015. The company covers a total area of 35000 square meters, with a total construction area of more than 21000 square meters and a green area of more than 6000 square meters. The company now has a total investment of more than 50 million yuan, with an annual output value of nearly 80 million yuan. The company has more than 200 employees, including 40 technicians of various types, 5 technicians with intermediate and intermediate titles, 4 licensed pharmacists, 16 with junior college degree or above in pharmacy and related majors, and 5 with college degree or above in other specialties. At present, there are 100 Chinese and Western medicine products, including Chinese and Western medicine tablets, granules, capsules and pills, as well as a comprehensive extraction workshop production line. The annual production capacity is 2.6 billion tablets, 200 tons pills, 400 tons granules and 300 million capsules. Anhui Renhe Pharmaceutical Co., Ltd. was established on December 15, 1991 with a registered capital of RMB 16.8 million. Wang Yufa is the legal representative, general manager and the fourth largest shareholder. The top three shareholders are Wang Qian, Wang Xin and Wang Yufu, each holding 30% of the shares. Wang Yufa holds 10% of the shares. Tianchang Yifan Pharmaceutical Co., Ltd. was established on January 31, 1997 with a registered capital of RMB 50 million. Xu Yungao is the legal representative and general manager. The company is a wholly-owned subsidiary of Hefei Yifan biomedical Co., Ltd. Hefei Yifan biomedical Co., Ltd. was established on November 26, 2003 with a registered capital of RMB 300 million. Ye Yiqun is the legal representative and general manager. The company is a wholly-owned subsidiary of Yifan Pharmaceutical Co., Ltd. < p > < p > Yifan Pharmaceutical Co., Ltd. was established on November 10, 2000 with a registered capital of 1.235 billion yuan. It was listed on the Shenzhen Stock Exchange on July 13, 2004. Cheng Xianfeng is the legal representative, actual controller, major shareholder, chairman and general manager. As of June 30, 2020, Cheng Xianfeng held 521 million shares, accounting for 42.21%. < / P > < p > Disclaimer: the purpose of this article reprinted by china.com finance and economics is to convey more information and does not represent the views and positions of the website. The content of this paper is for reference only and does not constitute investment advice. Investors operate accordingly and bear their own risks. < p > < p > Chinanet is a national key news website under the leadership of the Information Office of the State Council and managed by China foreign language publishing and Distribution Bureau. Through 11 versions in 10 languages, the website releases information 24 hours a day, which is an important window for China to carry out international communication and information exchange.